FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to orthopedics and arthrology and can be applied in treatment of ankylosing spondylitis. Methods by invention concern determination of antibody TNFα efficiency or its antigen-binding part, in treatment of ankylosing spondylitis with application of bio-marker of collagen degradation and bio-marker of synovitis. Sets by invention contain detected agent, which specifically recognises bio-marker of collagen degradation and bio-marker of synovitis, instructions for application and reagents for separation of sample from patient's organism.
EFFECT: intention application makes it possible to increase efficiency of ankylosing spondylitis treatment.
74 cl, 4 tbl, 4 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD AND OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT FOR INHIBITING HUMAN TNF ACTIVITY, APPLYING THE OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT AS INGREDIENT FOR PRODUCING MEDICAMENT | 1997 |
|
RU2270030C2 |
RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) | 2005 |
|
RU2458704C9 |
ISOLATED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, ISOLATED NUCLEIC ACID (VARIANTS), RECOMBINANT EXPRESSION VECTOR, USING HOST-CELLS FOR EXPRESSION OF ANTIBODY AND METHOD FOR ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF ACTIVITY OF HUMAN TNFα | 1997 |
|
RU2268266C2 |
AUTOMATIC INJECTION DEVICE | 2007 |
|
RU2438721C2 |
AUTOMATIC INJECTOR | 2007 |
|
RU2575906C2 |
CRYSTALLINE ANTIBODIES AGAINST hTNFα | 2007 |
|
RU2486296C2 |
IMPROVED HIGH-CONCENTRATED LIQUID PREPARATIONS OF ANTIBODIES AGAINST TNF-ALPHA | 2011 |
|
RU2639386C2 |
HUMANISED ANTIBODIES AGAINST TNFα | 2012 |
|
RU2549700C1 |
ANTIBODY PURIFICATION | 2007 |
|
RU2466740C2 |
METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLARTHRITIS BY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | 2016 |
|
RU2728710C2 |
Authors
Dates
2012-01-10—Published
2006-10-31—Filed